热作用对人肝癌MHCC97细胞增殖、凋亡及NDRG2表达的影响  

The effect of hyperthermia on expresssion protein NDRG2 in human liver cancer MHCC97 cell

作　　者：蔡佳辰[1] 刘文超[1] 王倩荣[1] 郭燕[1] 陈战[2] 刘志佳[3] 

机构地区：[1]第四军医大学西京医院肿瘤中心,陕西西安710032 [2]第四军医大学西京医院肝胆外科,陕西西安710032 [3]第四军医大学免疫学教研室,陕西西安710032

出　　处：《现代肿瘤医学》2012年第3期446-450,共5页Journal of Modern Oncology

基　　金：国家自然科学基金资助项目(项目编号:30973437)

摘　　要：目的:探讨热作用对人肝癌细胞株MHCC97细胞的增殖、凋亡以及NDRG2蛋白表达的影响。方法:MHCC97细胞分为5组,43℃恒温分别加热0h(对照组)、0.5h、1h、1.5h、2h。各组热处理后继续37℃恒温培养。于3h、6h、9h、12h、24h,使用倒置显微镜观察细胞形态变化,MTT法检测各处理组细胞增殖情况,流式细胞仪检测细胞凋亡,Western blot检测NDRG2蛋白量的表达。结果:热处理后,细胞形态出现明显改变,细胞体积缩小,部分细胞脱落,加热2h培养24h者最为显著;热处理后,细胞增殖受抑制,以加热1h培养24h者最为明显(67.1%);流式细胞仪检测显示,凋亡百分比在加热2h培养12h者达最大值(58.4%);Western blot检测提示,加热1h培养24h者,NDRG2蛋白表达量最低。结论:热疗对肿瘤细胞具有杀伤和增殖抑制作用,并且能够诱导其凋亡,降低NDRG2蛋白的表达,以加热1h后培养24h效果最明显。Objective：To determine the effect of different duration of hyperthermia on morphology,proliferation,apoptosis and the expression of protein NDRG2 in liver cancer MHCC97 cell.Methods：MHCC97 cells were divided into 5 groups,separately heated at 43℃ for 0h（control group）,0.5h,1h,1.5h,and 2h,then cultured at 37℃.At 3h,6h,9h,12h,and 24h,the morphology was observed by microscrope,proliferation status was examined by MTT assay,apoptpsis rate was tested by flow cytometry,and NDRG2 expression was detected by western blot.Results：The hyperthermia caused the tumour cells shape changed,the cells were small,karyopyknosis,and partly fell off.The cell shape was significantly changed in the group of 2h-heated and 24h-cultured.The thermotherapy suppressed cell multiplication,the group of 1h-heated and 24h-cultured was changed significantly（67.1%）.Acording to the flow cytometry,apoptosis rate was decreased significantly in the group of 2h-heated and 12h-cultured（58.4%）.NDRG2 expression was markedly reduced in the group of 1h-heated and 24h-cultured.Conclusion：The hyperthermia can impair cancer cells,suppress the proliferation,cause apoptpsis,and reduce NDRG2 expression.The significant effect appears in the sample of 1h-heated and 24h-cultured.

关 键 词：肝癌细胞 热疗 NDRG2 

分 类 号：R730.55[医药卫生—肿瘤] R735.7[医药卫生—临床医学]